$JZZI Based on Latest Research, JZZ Technologies, Inc. Announces New Immune Boost and Anti-Inflammatory Products Developed Through Nutrific Inc.
https://www.newsfilecorp.com/release/108305
West Palm Beach, Florida--(Newsfile Corp. - December 22, 2021) - JZZ Technologies, Inc., (OTC Pink: JZZI) is advancing research being forwarded by its anticipated venture with Nutrific, Inc. and GenBio Inc. in order to provide a breakthrough immune boost and anti-inflammatory product line.
The new research focuses on the body's negative reaction to viruses, such as the SARS-2 virus among others. International research supports that this response is an unnatural reaction that should be treatable through immune boost and anti-inflammatory products.
The Nutrific products aim to specifically address the transduction (signaling) process in inflammatory disorders to mitigate the worst effects of a virus and the body's response to them.
These two areas represent massive markets where a relevant natural treatment could provide significant revenues through a patented treatment. The global immune health supplements market is projected to grow from $20.18 billion in 2021 to $31.50 billion in 2028 at a CAGR of 6.6% from 2021 to 2028 (source: Fortune Business Insights).Alongside the immune health market, the Global Anti-Inflammatory Therapeutics market size is estimated to grow at CAGR of almost 6% with USD 27.53 billion during the forecast period 2021-2024 (source: MarketWatch). These are the two markets that Nutrific expects to enter with its new products.
Based on GenBio Inc.'s own internal research in Australia with its CSO coordinating translational research, treatment must address the following factors:
Certain viruses initiate a reaction from the immune system which thus creates an inflammatory response, including Cytokine Storm (CS)
CS is an accelerated production of an array of pro-inflammatory cytokines
CS then instigates different inflammatory pathways via their receptors on immune and tissue cells
This creates a variety of symptoms. CS can be a life-threatening clinical condition in which the excessive overproduction of both inflammatory cytokines and excessive activation of immune cells leads to medical complications
Current research focus by the GenBio team is on identifying natural extracts (and their key antioxidant molecules) than can reduce the intensity/severity of CS, particularly in the early stages. Particular attention will be paid to attempt to confine mechanisms of action to dampening specific immune pathways without impairing the host defense
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (e.g., obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19, but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders
Giles Tilley, CEO Of GenBio Inc., stated, "Significantly, these issues all attest to the immediate use of rare bioactive Australian natural extracts in the reduction of anti-inflammatory or anti thrombotic situations in a system wide occurrence in both healthy and overweight/obese populations."
"Metabolic dysfunction might lead to a baseline state of chronic inflammation, given that proinflammatory cytokines, such as TNFα, IL-6, and IL-1β, are upregulated in the adipose tissue of patients with metabolic syndrome," added Tilley.
As part of its efforts to keep pace with the significant expansion that its biotechnology and biosciences operations will create, JZZ Technologies Inc. is reviewing the potential for new corporate headquarters. Management is in discussions with several governmental and trade groups to establish the best, most flexible solution for the scaling of the company for the foreseeable future.
https://www.newsfilecorp.com/release/108305
West Palm Beach, Florida--(Newsfile Corp. - December 22, 2021) - JZZ Technologies, Inc., (OTC Pink: JZZI) is advancing research being forwarded by its anticipated venture with Nutrific, Inc. and GenBio Inc. in order to provide a breakthrough immune boost and anti-inflammatory product line.
The new research focuses on the body's negative reaction to viruses, such as the SARS-2 virus among others. International research supports that this response is an unnatural reaction that should be treatable through immune boost and anti-inflammatory products.
The Nutrific products aim to specifically address the transduction (signaling) process in inflammatory disorders to mitigate the worst effects of a virus and the body's response to them.
These two areas represent massive markets where a relevant natural treatment could provide significant revenues through a patented treatment. The global immune health supplements market is projected to grow from $20.18 billion in 2021 to $31.50 billion in 2028 at a CAGR of 6.6% from 2021 to 2028 (source: Fortune Business Insights).Alongside the immune health market, the Global Anti-Inflammatory Therapeutics market size is estimated to grow at CAGR of almost 6% with USD 27.53 billion during the forecast period 2021-2024 (source: MarketWatch). These are the two markets that Nutrific expects to enter with its new products.
Based on GenBio Inc.'s own internal research in Australia with its CSO coordinating translational research, treatment must address the following factors:
Certain viruses initiate a reaction from the immune system which thus creates an inflammatory response, including Cytokine Storm (CS)
CS is an accelerated production of an array of pro-inflammatory cytokines
CS then instigates different inflammatory pathways via their receptors on immune and tissue cells
This creates a variety of symptoms. CS can be a life-threatening clinical condition in which the excessive overproduction of both inflammatory cytokines and excessive activation of immune cells leads to medical complications
Current research focus by the GenBio team is on identifying natural extracts (and their key antioxidant molecules) than can reduce the intensity/severity of CS, particularly in the early stages. Particular attention will be paid to attempt to confine mechanisms of action to dampening specific immune pathways without impairing the host defense
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (e.g., obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19, but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders
Giles Tilley, CEO Of GenBio Inc., stated, "Significantly, these issues all attest to the immediate use of rare bioactive Australian natural extracts in the reduction of anti-inflammatory or anti thrombotic situations in a system wide occurrence in both healthy and overweight/obese populations."
"Metabolic dysfunction might lead to a baseline state of chronic inflammation, given that proinflammatory cytokines, such as TNFα, IL-6, and IL-1β, are upregulated in the adipose tissue of patients with metabolic syndrome," added Tilley.
As part of its efforts to keep pace with the significant expansion that its biotechnology and biosciences operations will create, JZZ Technologies Inc. is reviewing the potential for new corporate headquarters. Management is in discussions with several governmental and trade groups to establish the best, most flexible solution for the scaling of the company for the foreseeable future.
